Why is Trabectedin not available on the domestic market?

Trabectedin, as an anti-cancer drug approved in Europe and the United States, has long attracted attention. However, it has not been able to be launched in China so far due to various factors. First of all, drug introduction and approval require a large amount of clinical data to support it. Although trabectedin has unique value in the field of soft tissue sarcoma, its indications are relatively narrow and the target patient group is not large. This "niche market" characteristic has led companies to be more cautious in balancing clinical trial investment and returns, which directly affects the enthusiasm for domestic R&D and filing.

Secondly, drug prices and medical insurance policies are also important considerations. Trabectedin is a high-priced anti-cancer drug in Europe and is often used in multi-line treatment with a long treatment cycle. In the domestic medical system, if you want to enter the medical insurance directory, you need to have a clear economic evaluation and clinical benefit value. For drugs that have not yet carried out large-scale local clinical trials, it is difficult to quickly accumulate such data, making medical insurance access more difficult. In other words, even if it has been proven effective abroad, without the support of clinical research related to domestic patients, it is often difficult to promote marketing and medical insurance coverage.

Furthermore, although soft tissue sarcoma has a certain incidence rate in my country, it is generally classified as a rare disease. Compared with common cancer types such as lung cancer and breast cancer, the market demand is limited, which also makes multinational pharmaceutical companies more cautious when introducing them. At the same time, the research and development of similar drugs in China is accelerating, and some local companies are developing drugs with similar mechanisms or more targeted drugs, which has distracted the market prospects of trabectedin to a certain extent.

Overall, the failure of trabectedin to be launched in China is the result of multiple factors: limited market capacity, insufficient economic benefits, lack of local clinical data, and difficulty in matching medical insurance policies.

Reference materials:https://www.drugs.com/monograph/trabectedin.html